A trial of Pfizer’s experimental pill against Covid-19 reduced the chances of hospitalization or death for adults at risk of serious illness by 89 percent, the company confirmed Friday. The conclusions were so conclusive that the trials ended early after controlling 1,219 volunteers.
Pzifer shares started Friday in the United States with gains of 9 percent to $ 47.80, according to forward trading data from finanzas.com collected at 2:30 p.m. from Madrid.
The results appear to improve those seen with Merc’s molnupiravir pill, which last month demonstrated its ability to cut the chance of dying or being hospitalized in half for Covid-19 patients, who are also at high risk of severe disease. .
Full trial data is not yet available from either company.
Pfizer said it plans to send the results of interim trials of its pill, which is given in combination with an older antiviral called Ritonavir, to the U.S. Food and Drug Administration, as part of the emergency use request. which he presented in October.
The combination treatment, which will be branded Paxlovid, consists of three pills administered twice a day.